Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goodkin, D. E.
Right arrow Articles by Neilley, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goodkin, D. E.
Right arrow Articles by Neilley, L.
NEUROLOGY 1998;51:239-245
© 1998 American Academy of Neurology

A phase II study of IV methylprednisolone in secondary-progressive multiple sclerosis

D. E. Goodkin, MD, R. P. Kinkel, MD, B. Weinstock-Guttman, MD, S. VanderBrug Medendorp, MPH, M. Secic, MS, D. Gogol, RN, J. E. Perryman, M. M. Uccelli, BA and L. Neilley, NP

From the Mellen Center for Multiple Sclerosis Treatment and Research (Drs. Kinkel and Weinstock-Guttman, and S. VanderBrug Medendorp, M. Secic, D. Gogol, J.E. Perryman, and M.M. Uccelli), Cleveland, OH; and the USF/Mt. Zion Multiple Sclerosis Center (Dr. Goodkin and L. Neilley), San Francisco, CA.

Address correspondence and reprint requests to Dr Goodkin, the UCSF/Mt. Zion Multiple Sclerosis Center, 1600 Divisadero St., San Francisco, CA 94115.

Objective: To compare the tolerability and efficacy of two doses of IV methylprednisolone in patients with secondary-progressive MS.

Methods: IV methylprednisolone administered in high or low dose every other month for up to 2 years to 108 patients with secondary-progressive MS.

Results: No significant difference in efficacy with the primary outcome, a comparison of the proportions of patients in each treatment group who experienced sustained progression of disability. A relative treatment effect was detected with the high-dose regimen as measured by the preplanned secondary analysis, a comparison of time to onset of sustained progression of disability. Drug-related adverse events were observed more frequently in high-dose recipients but serious drug-related adverse events were uncommon, and cessation of study drug was only required in one patient.

Conclusion: The results of the secondary analysis of this study suggest that a phase III trial of corticosteroids for secondary-progressive MS is warranted.

Supported by the National Multiple Sclerosis Society (RG2350-A-3, Dr. Goodkin). Methylprednisolone and placebo tablets were supplied by The Upjohn Company, Kalamazoo, MI.

Received October 7, 1997. Accepted in final form March 28, 1998.




This article has been cited by other articles:


Home page
 Mult SclerHome page
J. Cohen, P. Calabresi, S. Chakraborty, K. Edwards, T. Eickenhorst, W. Felton III, E. Fisher, R. Fox, A. Goodman, C. Hara-Cleaver, et al.
Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data
Multiple Sclerosis, April 1, 2008; 14(3): 370 - 382.
[Abstract] [PDF]

Home page
 NeurologyHome page
D. Pohl, E. Waubant, B. Banwell, D. Chabas, T. Chitnis, B. Weinstock-Guttman, S. Tenembaum, and for the International Pediatric MS Study Group
Treatment of pediatric multiple sclerosis and variants
Neurology, April 17, 2007; 68(16_suppl_2): S54 - S65.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
E. M. Frohman, O. Stuve, E. Havrdova, J. Corboy, A. Achiron, R. Zivadinov, P. S. Sorensen, J. T. Phillips, B. Weinshenker, K. Hawker, et al.
Therapeutic Considerations for Disease Progression in Multiple Sclerosis: Evidence, Experience, and Future Expectations
Arch Neurol, October 1, 2005; 62(10): 1519 - 1530.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
L. Kappos
Effect of drugs in secondary disease progression in patients with multiple sclerosis
Multiple Sclerosis, June 1, 2004; 10(1_suppl): S46 - S55.
[Abstract] [PDF]

Home page
 Mult SclerHome page
L. Kappos
Effect of drugs in secondary disease progression in patients with multiple sclerosis
Multiple Sclerosis, May 1, 2004; 10(3_suppl): S46 - S55.
[Abstract] [PDF]

Home page
 NeurologyHome page
P. A. Calabresi
Considerations in the treatment of relapsing-remitting multiple sclerosis
Neurology, April 23, 2002; 58(90084): S10 - 22.
[Abstract] [Full Text]

Home page
 NeurologyHome page
R. Zivadinov, R. A. Rudick, R. De Masi, D. Nasuelli, M. Ukmar, R. S. Pozzi-Mucelli, A. Grop, G. Cazzato, and M. Zorzon
Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS
Neurology, October 9, 2001; 57(7): 1239 - 1247.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
N D Richert, J L Ostuni, C N Bash, T P Leist, H F McFarland, and J A Frank
Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis
Multiple Sclerosis, February 1, 2001; 7(1): 49 - 58.
[Abstract] [PDF]

Home page
 Mult SclerHome page
M. J Hohol, M. J Olek, E J. Orav, L. Stazzone, D. A Hafler, S. J Khoury, D. M Dawson, and H. L Weiner
Treatment of progressive multiple sclerosis with pulse cyclophosphamidel methylprednisolone: Response to therapy is linked to the duration of progressive disease
Multiple Sclerosis, December 1, 1999; 5(6): 403 - 409.
[Abstract] [PDF]

Home page
 NeurologyHome page
R. W. Beck, D. E. Goodkin, and R. P. Kinkel
A phase II study of IV methylprednisolone in secondary progressive MS
Neurology, March 1, 1999; 52(4): 894 - 894.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by AAN Enterprises, Inc.